Payment overview · 2025
General Payments
$176,174.14
212 reported records · 30 companies
Healthcare provider profile · identity verified
Jonathan Asif Abbas, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · NASHVILLE, TN · NPI 1316145253
Verified facts
What the public records show
CMS Open Payments records show Jonathan Asif Abbas, MD received $176,174.14 in general payments during 2025 across 212 reported records.
ABBVIE INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Iclusig, Jakafi, Scemblix, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Venclexta by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Venclexta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jakafi by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SCEMBLIX as an associated drug or biological on 10426 records involving 5114 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Scemblix by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ICLUSIG as an associated drug or biological on 3588 records involving 2461 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Iclusig by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33,667.30 | 19.1% | 32 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28,647.27 | 16.3% | 20 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $23,183.24 | 13.2% | 31 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18,750.85 | 10.6% | 15 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $12,813.40 | 7.3% | 16 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $12,172.68 | 6.9% | 7 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $12,169.70 | 6.9% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $11,371.50 | 6.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $10,039.59 | 5.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,165.21 | 2.4% | 9 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $2,629.19 | 1.5% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $2,170.00 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,840.51 | 1.0% | 4 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $1,033.58 | 0.6% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $430.42 | 0.2% | 13 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $208.24 | 0.1% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $151.13 | 0.1% | 6 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $146.82 | 0.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $96.15 | 0.1% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $90.21 | 0.1% | 3 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $88.94 | 0.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $72.60 | 0.0% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $46.97 | 0.0% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $46.69 | 0.0% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $32.44 | 0.0% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $24.19 | 0.0% | 1 | 2025 |
| BeiGene USA, Inc. | Unresolved — no canonical attribution shown | $23.91 | 0.0% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $23.20 | 0.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.27 | 0.0% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.94 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $139,084.50 | 48 |
| Consulting Fee | $20,385.50 | 10 |
| Travel and Lodging | $7,935.47 | 34 |
| Food and Beverage | $6,158.67 | 119 |
| Honoraria | $2,610.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $26,937.58 | 16 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $24,924.64 | 30 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $18,750.85 | 15 | 2025 |
Source payment records
|
|||||
| Jakafi Normalized: jakafi |
Drug | Incyte Corporation | $18,677.78 | 24 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $11,371.50 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C., Merck Sharp & Dohme LLC | $11,025.96 | 9 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $10,039.59 | 4 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $7,233.68 | 9 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $5,762.65 | 7 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $4,505.46 | 7 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $4,095.23 | 8 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $2,629.19 | 2 | 2025 |
Source payment records
|
|||||
| ELZONRIS Normalized: elzonris |
Drug | Stemline Therapeutics Inc. | $2,170.00 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $266.06 | 5 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $208.24 | 2 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $146.82 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $139.49 | 7 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $99.24 | 4 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $88.94 | 3 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $72.60 | 3 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $70.00 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $62.78 | 2 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $55.45 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $46.97 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $32.44 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $26.51 | 1 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| PEMAZYRE Normalized: pemazyre |
Drug | Incyte Corporation | $25.34 | 2 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $24.87 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeiGene USA, Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ICLUSIG iclusig |
2025 | Iclusig | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Jakafi jakafi |
2025 | Jakafi | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SCEMBLIX scemblix |
2025 | Scemblix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
54 | 25 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
54 | 25 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | SCEMBLIX open payments reported associated product |
CMS Open Payments — General Payments 10426 supporting records · 5114 recipient NPIs · example record 1200004731 |
Scemblix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | ICLUSIG open payments reported associated product |
CMS Open Payments — General Payments 3588 supporting records · 2461 recipient NPIs · example record 1223616292 |
Iclusig · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Valacyclovir | Valacyclovir Hcl | 84 | 24 |
| Voriconazole | Voriconazole | 68 | 23 |
| Venclexta | Venetoclax | 54 | 25 |
| Levofloxacin | Levofloxacin | 50 | 20 |
| Jakafi | Ruxolitinib Phosphate | 28 | suppressed |
| Revlimid | Lenalidomide | 26 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | 11 |
| Prednisone | Prednisone | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Onureg | Azacitidine | 19 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Xospata | Gilteritinib Fumarate | 14 | suppressed |
| Iclusig | Ponatinib Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Scemblix | Asciminib Hydrochloride | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176,174.14 · 212 records | ABBVIE INC. | ADCETRIS, BESREMI, BLINCYTO, BREYANZI, BRUKINSA, CALQUENCE, DARZALEX, Doptelet, ELREXFIO, ELZONRIS, EPKINLY, Enhertu, Fabhalta, ICLUSIG, IMBRUVICA, Jakafi, KEYTRUDA, LIBTAYO, MONJUVI, OJJAARA, OPDIVO, OPDUALAG, PEMAZYRE, PLUVICTO, PYRUKYND, Polivy, REBLOZYL, REVUFORJ, RYTELO, SARCLISA, SCEMBLIX, TALVEY, TECVAYLI, TEVIMBRA, Tibsovo, Trodelvy, VENCLEXTA, Vanflyta, Vonjo, WELIREG, Yescarta, ZEPZELCA, ZYNLONTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Iclusig play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error